Affordable Access

deepdyve-link
Publisher Website

Self-reported taste and smell alterations and the liking of oral nutritional supplements with sensory-adapted flavors in cancer patients receiving systemic antitumor treatment.

Authors
  • de Haan, Jacco J1
  • Renken, Remco J2
  • Moshage, Yvette3
  • Kluifhooft, Daniëlle A3
  • Corbier, Camille4
  • Daly, Louise E4
  • Blanchard, Hélène4
  • Reyners, Anna K L3
  • 1 Department of Medical Oncology, University Medical Center Groningen, PO Box 30.001, 9700RB, Groningen, The Netherlands. [email protected] , (Netherlands)
  • 2 Department of Cognitive Neuroscience Center, University Medical Center Groningen, Groningen, The Netherlands. , (Netherlands)
  • 3 Department of Medical Oncology, University Medical Center Groningen, PO Box 30.001, 9700RB, Groningen, The Netherlands. , (Netherlands)
  • 4 Danone Nutricia Research, Utrecht, The Netherlands. , (Netherlands)
Type
Published Article
Journal
Supportive Care in Cancer
Publisher
Springer-Verlag
Publication Date
Oct 01, 2021
Volume
29
Issue
10
Pages
5691–5699
Identifiers
DOI: 10.1007/s00520-021-06049-4
PMID: 33629188
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Taste and smell alterations (TAs and SAs) are often reported by patients with cancer receiving systemic antitumor therapy and can negatively impact food intake and quality of life. This study aimed to examine the occurrence of TAs and SAs and investigate the impact of TAs on overall liking of oral nutritional supplements (ONS) with warming and cooling sensations. Patients receiving systemic antitumor therapy completed a questionnaire on sensory alterations and evaluated overall liking of 5 prototype flavors of Nutridrink® Compact Protein (hot tropical ginger (HTG), hot mango (HM), cool red fruits (CRF), cool lemon (CL), and neutral (N)) on a 10-point scale via a sip test. Differences between patients with and without TAs were investigated using permutation analysis. Fifty patients with various cancer types and treatments were included. Thirty patients (60%) reported TAs and 13 (26%) experienced SAs. Three flavors were rated highly with a liking score > 6 (CRF 6.8 ± 1.7; N 6.5 ± 1.9; HTG 6.0 ± 2.0). Larger variation in ONS liking scores was observed in patients with TAs with or without SAs (4.5-6.9 and 4.6-7.2, respectively) vs. patients without TAs (5.9-6.5). TAs were associated with increased liking of CRF (Δ = + 0.9) and N (Δ = + 1.0) flavors. TAs and SAs are common in patients with cancer undergoing systemic antitumor therapy. Patients with TAs were more discriminant in liking of ONS flavors compared to patients without TAs, and sensory-adapted flavors appeared to be appreciated. The presence of TAs should be considered when developing or selecting ONS for patients with cancer. Registration at ClinicalTrials.gov (NCT03525236) on 26 April 2018. © 2021. The Author(s).

Report this publication

Statistics

Seen <100 times